Holen Sie sich die Stockscreener-App
20.82
1.07%
0.22
Handel nachbörslich:
20.82
Schlusskurs vom Vortag:
$20.60
Offen:
$20.76
24-Stunden-Volumen:
916.99K
Relative Volume:
1.00
Marktkapitalisierung:
$2.48B
Einnahmen:
$434.48M
Nettoeinkommen (Verlust:
$68.15M
KGV:
20.61
EPS:
1.01
Netto-Cashflow:
$114.96M
1W Leistung:
-11.22%
1M Leistung:
-1.98%
6M Leistung:
+26.26%
1J Leistung:
+50.76%
1-Tages-Spanne:
$20.53
$21.19
1-Wochen-Bereich:
$20.44
$23.73
52-Wochen-Spanne:
$13.00
$24.27
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Vergleichen Sie CPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CPRX | 20.82 | 2.48B | 434.48M | 68.15M | 114.96M | 1.01 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated at Stephens - MarketBeat
Principal Financial Group Inc. Has $11.45 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals chairman sells shares worth $3.1 million - Investing.com
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Royce & Associates LP - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Board Member Trades $11.51M In Company Stock - Benzinga
Catalyst Pharmaceuticals chairman sells $11.5 million in stock - Investing.com
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - GlobeNewswire
Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve - Simply Wall St
Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point - Yahoo Finance
Los Angeles Capital Management LLC Buys 123,020 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $30.50 - MarketBeat
CWA Asset Management Group LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $36.00 at Truist Financial - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Meritage Portfolio Management - MarketBeat
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highli - GuruFocus.com
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceuticals' (CPRX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2024 Earnings Call Transcript - Insider Monkey
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case - Yahoo Finance
Catalyst Pharmaceuticals Reports Strong Q3 2024 Earnings - TipRanks
Earnings call: Catalyst Pharma reports robust Q3 results, raises guidance - Investing.com
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024 - Marketscreener.com
Earnings call: Catalyst Pharma reports robust Q3 results, raises guidance By Investing.com - Investing.com Canada
Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings - Simply Wall St
Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides - The Bakersfield Californian
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Report Prev - GuruFocus.com
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Catalyst Pharmaceuticals Q3 2024 Earnings Preview - MSN
Catalyst Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch
A Peek at Catalyst Pharmaceuticals's Future Earnings - Benzinga
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Catalyst Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Catalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
DekaBank Deutsche Girozentrale Increases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (CPRX) to Release Quarterly Earnings on Wednesday - MarketBeat
Zacks.com featured highlights include Vertiv, Limbach, Atour Lifestyle and Catalyst Pharmaceuticals - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Holdings Boosted by Allspring Global Investments Holdings LLC - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 12-Month HighHere's Why - MarketBeat
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):